Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07728253) titled 'Probiotic IBNI617 for Moderate to Severe Depression' on July 22.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: IBIOME BIOTECHNOLOGY CO., LTD
Condition:
Major Depressive Disorder (MDD)
IBNI617
Intervention:
Other: Live biotherapeutic product
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: August 2026
Target Sample Size: 148
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT0772825...